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Abstract
The synthesis and biochemical activities of novel water-soluble β-lactam analogues of
combretastatin A-4 are described. The first series of compounds investigated, β-lactam
phosphate esters 7a, 8a and 9a, exhibited potent antiproliferative activity and caused
microtubule disruption in human breast carcinoma-derived MCF-7 cells. They did not
inhibit tubulin polymerisation in vitro, indicating that biotransformation was necessary
for their antiproliferative and tubulin binding effects in MCF-7 cells. The second series of
compounds, β-lactam amino acid amides (including 10k and 11l) displayed potent
antiproliferative activity in MCF-7 cells, disrupted microtubules in MCF-7 cells and also
inhibited the polymerisation of tubulin in vitro. This indicates that the β-lactam amides
did not require metabolic activation to have antiproliferative effects, in contrast to the
phosphate series. Both series of compounds caused mitotic catastrophe and apoptosis in
MCF-7 cells. Molecular modelling studies indicated potential binding conformations for
the β-lactam amino acid amides 10k and 11l in the colchicine-binding site of tubulin. Due
to their aqueous solubility and potent biochemical effects, these compounds are
promising candidates for further development as microtubule-disrupting agents.
Keywords
Antiproliferative; beta-lactam; combretastatin A-4; prodrug; solubility; tubulin.
Abbreviations
CA-1

Combretastatin A-1

CA-4

Combretastatin A-4

DIPEA

Diisopropylethylamine

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

2

NAC

N-Acetylcolchicine

PBS

Phosphate buffered saline

1. Introduction
Solubility limitations to oral drug delivery are frequently encountered in drug
development [1, 2]. There are many formulation and drug design strategies that can be
used to overcome solubility issues, such as use of surfactants and co-solvents. Design of
soluble prodrugs is a routine technique used to overcome solubility problems [3]. We
have recently reported a series of β-lactams with extremely potent antiproliferative
effects [4, 5]. These compounds are amongst the most potent analogues of combretastatin
A-4 reported to date, but their further development is limited by lack of aqueous
solubility. Hence, we designed phosphate- and amino acid-containing derivatives of the
β-lactams to improve their pharmacokinetic profile.
1.1 Phosphate ester prodrugs
Phosphate ester prodrugs are useful for phenolic and amino-containing poorly watersoluble drugs to enhance their aqueous solubility. Phosphate prodrugs display excellent
chemical stability and rapid bioconversion in vivo to the parent drug by phosphatases
present in the intestinal brush border or in the liver [1]. Examples of commercially
available phosphate prodrugs include the anti-epileptic fosphenytoin [3], the antiviral
fosamprenavir and the steroid prednisolone phosphate [1]. Phosphate prodrugs of tubulinbinding agents are known, for example those of N-acetylcolchicine (1), combretastatin A4 (2), combretastatin A-1 (3) and phenstatin (4, Figure 1). Phosphate prodrug 1a (Figure
1) demonstrated increased water-solubility and delayed metabolism compared to 1.
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Analogue 1a showed comparative effects to 1 in vivo but did not inhibit in vitro
polymerisation of tubulin, indicating that phosphate compound 1a itself is inactive and
requires enzymatic activation in vivo [6]. Prodrug 1a was in clinical trials in the United
States for the treatment of metastatic renal cell carcinoma, but these were halted due to
cardiotoxicity problems [7].

Combretastatin prodrugs have been extensively investigated, including phosphate
prodrugs of combretastatin A-4 (CA-4, 2, Figure 1) [8], combretastatin A-1 (CA-1, 3,
Figure 1) [9], combretastatin B-1 [9], stilstatins 1 and 2 [10] and iodocombretastatins
[11]. Due to the sparing aqueous solubility of 2, initial formulation attempts were
unsuccessful [8]. The phosphate ester prodrug CA-4P (2a, Figure 1) had excellent water
solubility, good stability and good cell growth inhibitory activity, with a mean panel GI50
of 6.89 nM (compared to 6.61 nM for 2) in the NCI screen [8]. Prodrug 2a is rapidly
dephosphorylated to 2 in vivo with a half-life of a few minutes [12]. It is under evaluation
in phase 3 trials for treatment of anaplastic thyroid cancer and in phase 2 trials for nonsmall cell lung cancer and platinum-resistant ovarian cancer [13]. Phenstatin (4, Figure 1)
is a benzophenone-type compound structurally similar to 2 with potent antiproliferative
and tubulin-binding activity but poor aqueous solubility. A phosphate prodrug (4a, Figure
1) was prepared to improve water-solubility and had equivalent antiproliferative activity
compared to the parent compound 4 [14].
1.2 Amino Acid Prodrugs
Like phosphate prodrugs, amino acid prodrugs also confer the advantage of increased
aqueous solubility to poorly soluble drug molecules. Additionally, drugs with an amino
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acid residue may be substrates for peptide transporters, allowing them to be taken up by
endogenous transporters in the intestinal epithelium [1]. Of a series of amino acid
prodrugs of CA-4 amino analogue 5 (Figure 2), serine derivative 5a retained potent
antiproliferative activity (IC50 value of 27.2 nM in colon 26 cells compared to 2.8 nM for
5) while improving the solubility in human plasma compared to 5 from 1.4 mg/mL to 3.3
mg/mL [15]. Prodrug 5a is in clinical trials for advanced-stage soft tissue sarcoma, solid
tumours and advanced solid tumours [16]. Amino acid prodrugs of combretastatin A-2
amino derivative 6 (Figure 2) have also been reported, with glycine and tyrosine amides
possessing the most potent antiproliferative effects (mean IC50 value of 20 nM for glycine
derivative 6a and 17 nM for tyrosine derivative, compared to 13 nM for 6, across a panel
of six human cell lines). The amide prodrugs of 6 displayed little inhibition of tubulin
polymerisation in vitro, indicating a requirement for bioactivation [17].

β-Lactams for further development were selected from our previous studies on the basis
of their potency in antiproliferative assays and the presence of suitable functional groups
(phenolic and amino) for modification (7-11, Figure 3) [4, 5, 18]. The aim of this work
was to synthesise water-soluble β-lactams with potent antiproliferative effects for
pharmaceutical use and to characterise their biochemical effects.

2. Chemistry
Phosphate esters of three potent phenolic β-lactams (7, 8 and 9) [4, 5] were prepared in
two steps (Scheme 1). Benzyl-protected compound 9c was used to achieve selective
esterification of the phenol at the C-4 position of 9. Reaction with dibenzylphosphite was
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achieved using diisopropylethylamine (DIPEA) and dimethylaminopyridine (DMAP) to
give 7b, 8b and 9b in yields up to 74% (Scheme 1, step a). Introduction of the
dibenzylphosphite group to the phenol of the β-lactam was confirmed by the appearance
of signals integrating for 4 protons at approximately δ 5.15 ppm in the 1H NMR spectra
of 7b, 8b and 9b, attributable to the benzylic CH2 protons. The final step was
hydrogenolysis of the benzyl protecting groups to prepare 7a, 8a and 9a in high yields
(Scheme 1, step b). The deprotection of 7b was initially achieved in 72% yield by
treatment with bromotrimethylsilane. Debenzylation (H2/PdC) of the β-lactam
intermediates in high yield was successful without decomposition of the β-lactam ring.

Initial investigation into potential amino acid prodrugs of 7 were directed at preparation
of amino acid esters. The Cbz-protected alanine ester 7e and phenylalanine ester 7f along
with N-acetyl glycine ester 7g, were obtained by DCC/DMAP coupling of the phenolic
moiety of 7 with the appropriate amino acids (Scheme 2). Removal of the Cbz protecting
group from 7e afforded the alanine ester 7h. However, isolation of the corresponding
phenylalanine and glycine esters proved difficult due to very rapid hydrolysis to the
phenol 7. The preparation of a number of additional Cbz protected amino acid esters of 7
was investigated, but in each case the deprotected ester was rapidly hydrolysed. These
esters are not suitable for further prodrug development. The acetate and benzoate esters 7i
and 7j were prepared by Staudinger reaction of corresponding imines 12a and 12b with
phenylacetyl chloride. A basic ether derivative 7l was also synthesised (Scheme 2). The
ether linkage would not be susceptible to hydrolysis in vivo while the basic side chain
may improve the water solubility of the derivative. Reaction of the imine 12c with 1,2-
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dibromoethane afforded the bromide 12d, which was then treated with phenylacetyl
chloride to produce the β-lactam product 7k. Reaction of the bromide 7k with
methylamine afforded the required product 7l in low yield (30%) as the basic reaction
conditions resulted in extensive cleavage of the β-lactam ring.

In order to prepare further amino acid β-lactams amides, amino-containing azetidinones
10 and 11 [4] were coupled to a series of protected L-amino-amino acids. DCC, with
DMAP and HOBt.H2O, was used to couple either 10 or 11 to the carboxylate moiety of
amino acids to afford the products 10a-10f and 11a-11h (Schemes 3 and 4). Use of
polymer-supported DCC gave higher yields and led to more facile isolation of the
product. This resin contains 1% cross-linked poly(styrene-co-divinylbenzene) with a
typical loading of 1.3 mmol/g of carbodiimide. The amino group of the amino acid was
protected during the coupling reaction with either Fmoc or Cbz. Selected amino acid
precursors (serine and tyrosine) also required benzyl protection of their phenolic groups
(compounds 10d, 11f and 11g). The required lysine precursor was available with both
amino groups protected with the Fmoc group. Products were obtained in yields of over
44% with the exception of lysine-analogue 10c (6%).

Initially the Fmoc-group was cleaved using the base piperidine [19, 20]. When 5%
piperidine in dichloromethane [21] was used to remove the Fmoc-group from amino acidβ-lactam conjugates, difficulties in purification of the product arose. A second method
using tetrabutylammonium fluoride (TBAF, 2 equivalents) and a thiol (1-octanethiol, 10
equivalents) to scavenge the liberated dibenzofulvene was investigated. This method
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removes the Fmoc group from a variety of amino acid conjugates in up to 100% yield
within 1 minute [22]. It was successfully applied to remove the Fmoc group from the βlactam derivatives 10a-10d and 11a - 11g (Scheme 3), giving easily isolated products 10g
- 10j and 11i - 11o in high yield, in less than 10 minutes as monitored by TLC. Cbz- and
Bn-groups were removed by hydrogenolysis (H2/PdC) from intermediates 10e, 10f, 10j,
11h, 11n and 11o to afford compounds 10k, 10l, 10m, 11p, 11q and 11r respectively
(Scheme 4).

3. Solubility
Selected compounds 9, 9a, 10, 10g, 11 and 11l were shown to be stable in stable in the
pH range 4-9 and in human plasma, with half-lives greater than 24 h (data not shown).
The solubility of the novel β-lactam derivatives was measured and compared to that of
the parent compounds. The phosphate derivatives showed increased aqueous solubility
compared to the insoluble parent compounds (Table 1). The phenolic β-lactams 7, 8 and 9
did not display any detectable aqueous solubility, while phosphate derivatives 7a, 8a and
9a were soluble at 0.3 mg/mL, 0.14 mg/mL and 0.45 mg/mL respectively in water,
greater than the recommended minimum solubility of 0.05 mg/mL which is desirable for
potential drug candidates [23]. The increase in solubility is reflective of the increase in
hydrophilicity of the molecules, as indicated by their lower cLogP values (Table 1). All
amino acid β-lactam amides assessed showed increased aqueous solubility compared to
parent β-lactams 10 and 11 (Tables 2 and 3). The highest solubility was obtained with the
alanine derivative 11j (0.37 mg/mL), which again is favourable compared to the
minimum desired value of 0.05 mg/mL. The observed increase in solubility due to the
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phosphate or amino acid group improves the pharmacokinetic profile of the parent
compound. Amide 7g and amine 7l were not useful as water soluble compounds.

4. Biochemical Results and Discussion
4.1. Antiproliferative Effects of Phosphate Ester and Amino Acid Amide β-Lactams
Stilbene 2 was insoluble in water and the development of 2a represented the most
successful prodrug of 2; it retained the activity of the parent compound, had improved
solubility and good stability [8]. Phosphate esters of three phenolic β-lactam compounds
with potent IC50 values in antiproliferative assays (7, 8 and 9) were prepared to
investigate if improvements in aqueous solubility could be obtained without
compromising antiproliferative activity. The antiproliferative activities of parent
compounds were also previously demonstrated in a variety of cell types in the NCI cell
line screen [4, 5]. The antiproliferative activity of all compounds was assessed using
human breast carcinoma MCF-7 cells.

The β-lactam phosphate esters 7a, 8a and 9a had IC50 values of 71 nM, 20 nM and 22 nM
respectively and had slightly decreased potency compared to the corresponding parent
compounds (Table 1). The IC50 values for the phosphate esters follow approximately the
same trend as their parent compounds, as 8 and 9 are more potent than 7, with 8a and 9a
are more potent than 7a.

The antiproliferative activity of β-lactam amino acid conjugates 10g-10i, 10k-10m, 11i11m and 11p-11r was assessed (Tables 2 and 3). Derivatives of compound 10 were
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extremely potent (Table 2), with alanine derivative 10h, phenylalanine derivative 10k
and valine derivative 10l showing activity greater than or equal to that of the parent
amino compound 10 (IC50 values of 27 nM, 35 nM and 51 nM respectively compared to
51 nM for 10). Valine derivative 11l (IC50 value of 460 nM) was the most potent
derivative of 11. Alanine (11j), serine (11q) and tyrosine (11r) derivatives also had IC50
values in the nanomolar range comparable to that of the parent compound 11 (760 nM,
780 nM and 740 nM respectively, 650 nM for 11).

4.2. Effects on Tubulin Polymerisation
Inhibition of tubulin polymerisation for existing phosphate prodrugs 1a, 2a and 4a differ,
with intact 1a [6] and 2a [24] displaying no intrinsic tubulin binding affinity while 4a
displays 40% of the activity of the parent compound 4 [14]. The effects of 5a on in vitro
tubulin polymerisation have not been reported, but it is known that amino acid amide
derivatives of 6, including 6a, do not inhibit the polymerisation of tubulin at
concentrations up to 40 μM [17]. It has previously been demonstrated that compounds 7,
8 and 9 inhibit the polymerisation of tubulin [4, 5]. Representative β-lactams 7a and 9a
(phosphate esters) and 10k and 11l (amino acid amides) were selected for in vitro tubulin
polymerisation studies.

Phosphate β-lactam esters 7a and 9a did not inhibit the in vitro polymerisation of tubulin
at a concentration of 10 μM (Figure 4). Given their potent antiproliferative effects in
MCF-7 cells, this result indicates that bioconversion is necessary for the biochemical
effects of the phosphate compounds. In contrast, the amino acid β-lactam conjugates 10k
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and 11l inhibited in vitro polymerisation of tubulin in a concentration dependent manner
(shown for 11l in Figure 5), with IC50 values of 2.4 µM and 5.2 µM respectively. This
indicates that bioconversion is not necessary for these compounds, although in vivo
cleavage of the amide linkage is extremely likely to occur. For example, it has been
reported that aminopeptidases on the surface of erythrocytes catalyse the cleavage of 5a
to 5 [21].

4.3. Immunofluorescence Studies
In addition to in vitro tubulin polymerisation studies, we investigated alterations in the
microtubule network induced by β-lactams 8a, 9a, 10k and 11l in MCF-7 cell culture by
confocal microscopy. Confocal analysis of MCF-7 cells stained with α-tubulin mAb
demonstrated a well organised microtubular network in control cells (Figure 6, A+E and
Figure 7, A+D). Exposure to any of the four β-lactam conjugates 8a, 9a, 10k and 11l for
16 h led to a complete loss of microtubule formation consistent with depolymerised
microtubules (Figures 6 and 7). Additionally, cells treated with β-lactams 8a, 9a, 10k and
11l contained multiple micronuclei - a phenomenon described as mitotic catastrophe.
Mitotic catastrophe is a type of programmed cell death in response to DNA damage,
characterised by multinucleated cells [25]. We have previously noted mitotic catastrophe
for related β-lactam derivatives [26]. The findings are in agreement with previously
published studies, where 2 induced mitotic catastrophe in non-small cell lung cancer cells
[27, 28] and 2a in chronic lymphocytic leukaemia cells [29]. Mitotic catastrophe has also
been demonstrated for 2 and related derivatives in both human endothelial cells
(HUVEC), human lung carcinoma cells (H460) [30] and human breast cancer cells
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(MCF-7) [26]. The confocal imaging results confirm that both the phosphate and amino
acid β-lactam conjugates are targeting tubulin.

4.4. Analysis of DNA Content by Flow Cytometry
We next examined the effects of 2, parent β-lactams 7, 8 and 9 and β-lactam derivatives
7a, 8a, 9a, 10k and 11l on the cell cycle of MCF-7 cells by flow cytometric analysis of
propidium iodide stained cells (Figure 8). In this whole-cell assay, both phosphate and
amino acid β-lactam prodrugs caused increases in the percentage of cells in the sub-G1
and G2/M phases, indicative of apoptosis and G2/M arrest respectively. There were no
significant differences in the percentage of cells in sub-G1 and G2/M phases between the
parent β-lactams and the derivatives.
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5. Molecular Modelling Studies
The tubulin binding and immunofluorescence studies clearly demonstrate that tubulin is
the target of the new β-lactam derivatives. Based on structural similarities between 2 and
the β-lactams reported in this study, we propose that they interact with the colchicine
binding site of tubulin as demonstrated for 2 and structurally related, conformationally
constrained analogues of 2 [30-32]. Molecular modelling studies were performed to
investigate potential interactions for the intact β-lactam amino acid amides 10k and 11l,
considering that they inhibited tubulin polymerisation without chemical or enzymatic
modification. The reported X-ray structure of tubulin cocrystallized with a colchicine
derivative, N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine, PDB entry
1SA0) was used for the docking study [33]. β-Lactams were isolated as racemic mixtures
and the presence of two enantiomers has been demonstrated [4]. Molecular modelling
studies were carried out with both enantiomers and results of the best fitting 3S*,4R*
enantiomer are illustrated. The β-lactam phosphate esters 7a, 8a and 9a had no effect in
the in vitro tubulin polymerisation assay, indicating that hydrolysis is required for their
effects, and therefore no molecular modelling was investigated for those compounds.

Molecular docking studies of parent compounds 10 and 11 (Figures 9A and 10A)
predicted similar interactions to those previously reported to be of importance for binding
at the colchicine site, including important interactions with Cys241 and Val318 [33, 34].
Additionally, there is direct bond between compound 11 and the Met259 residue. Both
compounds are orientated in a similar manner to DAMA-colchicine, with the 3,4,5-
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trimethoxyaryl A ring and 4-methoxyaryl B ring occupying the same position in the
binding pocket (Figures S1 and S3, Supplementary Information).

Comparison of the docked structures of 10 and 10k indicated that the core β-lactam, A
and B rings are orientated in the same way in the binding pocket (Figure 9A and B, and
Figures S1 and S2, Supplementary Information). All but one of the 24 binding contacts
for 10 are also predicted for 10k, the exception being an interaction with Asn249. The
phenylalanine substituent on ring C extends further and makes numerous additional
contacts, for example with Lys254 and Lys352 (Figure 9B). We have previously shown
that bulky substituents directly attached to ring C are detrimental to activity [4]. In this
series of β-lactams the potency of 10k in MCF-7 cells indicates that the linear chain
linking the two aromatic rings (ring C to the aromatic ring of phenylalanine) is essential
to maintain potent in vitro activity.

The docked structures of 11 and 11l are illustrated in Figure 10. Additional binding
interactions associated with the valine moiety are predicted for 11l, namely with Gln11,
Gly143, Ser178, Glu183, Tyr224 and Gln247. The predicted docking position for both
the core β-lactam and A rings is similar for these two structures. However, the
positioning of the B and C rings of both compounds is different (Figures S3 and S4,
Supplementary Information). We have previously noted this ‘flip’ in relative orientation
of the B and C rings for β-lactams when larger substitutents are present on ring B [26].
The orientation predicted for 11l is consistent with our previous experience that bulky
substitution to the B ring forces a change in molecular orientation within the colchicine
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binding site. This is not necessarily associated with a decrease in antiproliferative
activity, as 11l is more potent in MCF-7 cells than 11. However, we must once again
emphasize that hydrolysis to yield the parent amine compounds 10 and 11 is predicted to
occur in vivo prior to interaction with tubulin. These in silico studies provide useful
information for the development of future antiproliferative agents that interact with the
colchicine binding site of tubulin, possibly exploiting the additional binding interactions
predicted for 10k and 11l.

6. Discussion
Our previously reported β-lactams are amongst the most potent analogues of 2 known,
with selected compounds showing sub-nanomolar antiproliferative activity (e.g. IC50 for
9 in MCF-7 cells is 0.8 nM). However, these compounds are not sufficiently water
soluble for further development and a prodrug strategy was devised to improve this
physiochemical characteristic. Potentially useful prodrugs were synthesised including
three β-lactam phosphate esters, two β-lactam esters and eighteen amino acid amides. A
number of novel compounds exhibited greatly improved aqueous solubility compared to
the parent compounds.

The primary in vitro degradation pathway of concern for phosphates is hydrolysis, and
the electronic environment and substitution on the prodrug moiety may have profound
effects on stability [35]. Two previously reported prodrugs of 2 were found to be stable in
aqueous solution [36]. When the stability of phosphate ester prodrugs 2a and 3a was
evaluated in murine plasma, there was little evidence of dephosphorylation even after 3
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hours. In contrast, 2a and 3a were rapidly dephosphorylated in tumor (MAC29) and liver
preparations [37]. It is expected that rapid in vivo dephosphorylation would occur for the
β-lactam phosphates 7a, 8a and 9a in a manner similar to that documented for 2a [12]. In
vitro, a selection of representative β-lactam phosphate esters were demonstrated to be
stable in the pH range 4-9 and in plasma, with half-lives greater than 24 hours. The βlactam amino acid amides are also stable at three pH values (Table 4). These amides are
expected to be hydrolysed by peptidases in vivo in a similar fashion to 5a [21]. Further
detailed stability studies on the β-lactam phosphate esters and amino acid amides are
ongoing.

Biochemical profiling of the β-lactam derivatives confirmed their antiproliferative and
tubulin-targeting effects. For both series of compounds, antiproliferative activity was
noted in the nanomolar concentration range, with 8a, 9a, 7a and 10k having the lowest
IC50 values (20, 22, 71 and 27 nM respectively). Immunofluorescence microscopy studies
showed disruption of the microtubule network and mitotic catastrophe for both the
phosphate and amino acid series of analogues. In cell-cycle analysis the percentage of
cells in sub-G1 (indicative of cell death) was significantly increased compared to the
control.

In the antiproliferative, immunofluorescence and cell cycle analysis assays, whole cells
are used and it is expected that bioconversion of the β-lactam derivatives to the parent
compounds is possible. Both series of compounds had the same potent biochemical
effects in these assays. However, we noted a significant difference between the phosphate
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and amino acid analogues in the tubulin polymerisation assay, which uses isolated,
purified tubulin and in which metabolic enzymes are not present. In this assay, the
phosphate prodrugs did not inhibit tubulin polymerisation. The amino acid β-lactam
conjugates, taking 10k and 11l as representative examples, inhibited tubulin
polymerisation in vitro in the absence of enzymatic action. These results indicate that the
phosphate derivatives are true prodrugs requiring enzymatic activation, while the intact
amino acid derivatives are microtubule poisons in their own right. However, due to the
widespread presence of aminopeptidases in the blood, it is likely that they may be
hydrolysed in vivo before reaching their target site of action. Regardless of this, we have
demonstrated they can act as microtubule depolymerisers in either form.

7. Conclusion
We describe the synthesis and biochemical effects of novel series of antiproliferative
phosphate ester and amino acid amide β-lactam derivatives, designed to overcome the
pharmacokinetic hurdle of poor aqueous solubility observed for previously reported
compounds [4]. The novel compounds displayed increased aqueous solubility, which is
an advantage for drug delivery. The strategic modification of previously described βlactam CA-4 derivatives by inclusion of phosphate or amino acid moieties did not
adversely influence their antiproliferative and tubulin targeting properties, as determined
by antiproliferative assays, cell cycle assays and analysis of the microtubular network by
confocal microscopy. Novel derivatives had nanomolar antiproliferative IC50 values in
MCF-7 cells and disrupted the microtubule network. The potent activity and microtubule
disrupting effects of the β-lactam derivatives warrants further investigations.
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8. Experimental Methods
All reagents were commercially available and were used without further purification
unless otherwise indicated. IR spectra were recorded as thin films on NaCl plates or as
KBr discs on a Perkin-Elmer Paragon 100 FT-IR spectrometer. 1H and 13C NMR spectra
were obtained on a Bruker Avance DPX 400 instrument at 20oC, 400.13MHz for 1H
spectra, 100.61MHz for
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C spectra, in CDCl3, CD3OD or DMSO-d6 (internal standard

tetramethylsilane) by Dr. John O’Brien and Dr. Manuel Ruether in the School of
Chemistry, Trinity College Dublin. High resolution accurate mass determinations
(HRMS) for all final target compounds were obtained on a Micromass Time of Flight
mass spectrometer equipped with electrospray ionisation (ES) interface operated in the
positive ion mode at the High Resolution Mass Spectrometry Laboratory by Dr. Martin
Feeney in the School of Chemistry, Trinity College Dublin. Thin layer chromatography
was performed using Merck Silica gel 60 TLC aluminium sheets with fluorescent
indicator visualizing with UV light at 254 nm. Flash chromatography was carried out
using standard silica gel 60 (230-400 mesh) obtained from Merck. Analytical highperformance liquid chromatography (HPLC) to determine the purity of the final
compounds was performed using a Waters 2487 Dual Wavelength Absorbance detector, a
Waters 1525 binary HPLC pump, a Waters In-Line Degasser AF and a Waters 717plus
Autosampler. The column used was a Varian Pursuit XRs C18 reverse phase 150 x 4.6
mm chromatography column. Samples were detected using a wavelength of 254 nm. All
samples were analysed using acetonitrile (70%): water (30%) over 10 min and a flow rate
of 1 mL/min. The purity of the tested compounds was >95%. Polymer-supported DCC
was obtained from (Biotage®). Syntheses of imine 12c [18] and β-lactams 7, 8, 9, 10 and
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11 [4, 5] were achieved as previously reported. Experimental characterisation of
compounds 8a, 8b, 9a, 9b, 10a-10d, 10f-10j, 10l, 10m, 11a-11c, 11e-11k, 11m-11r is
contained in the supplementary information.

8.1 Chemical Synthesis
8.1.1. General procedure for synthesis of imines
The appropriate amine (10 mmol) was refluxed with the appropriate aldehyde (10 mmol)
in ethanol (50 mL) for 3 h. The reaction mixture was reduced in vacuo, and the resulting
solution was allowed to stand until solid product crystallized from solution. The resulting
imine was recrystallized from ethanol.
8.1.1.1. 2-Methoxy-5-(((3,4,5-trimethoxyphenyl)imino)methyl)phenyl acetate (12a)
was obtained from 3,4,5-trimethoxyaniline and 5-formyl-2-methoxyphenyl acetate as a
white powder (64% yield); mp 120 °C; IR (KBr disk) υmax: 1608 cm-1 (C=N); 1H NMR
(400 MHz, CDCl3) δ 2.22 (s, 3H, CH3), 3.85 (m, 12H, OCH3), 6.51 (s, 2H, ArH), 7.08 (d,
1H, J=4.5 Hz, ArH), 7.28 (s, 1H, ArH), 7.79 ( m, 1H, ArH), 8.39 (s, 1H, C=N); HRMS:
calculated for C19H22NO6: 360.1449; found 360.1430 [M+H]+.
8.1.1.2. 2-Methoxy-5-(((3,4,5-trimethoxyphenyl)imino)methyl)phenyl benzoate (12b)
was obtained from 3,4,5-trimethoxyaniline and 5-formyl-2-methoxyphenyl benzoate as
peach coloured crystals (75% yield); mp 120 °C; IR (KBr disk) υmax: 1611 cm-1 (C=N);
1

H NMR (400 MHz, CDCl3) δ 3.90 (m, 12H, OCH3), 7.11 (s, 1H, ArH), 7.28 (s, 2H,

ArH), 7.55 (m, 2H, ArH), 7.67 (m,1H, ArH), 7.83 (m, 2H, ArH), 8.24 (d, 2H, J=1 Hz,
ArH), 8.43 (s, 1H, C=N); HRMS: calculated for C24H24NO6: 422.1604; found
422.1582[M+H]+.
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8.1.2. General procedure for synthesis of 7b, 8b and 9b
Carbon tetrachloride (85 mmol) was added to a solution of appropriate phenol (17 mmol)
in acetonitrile (100 mL) at 0 °C. The resulting solution was stirred for 10 minutes prior to
addition of diisopropylethylamine (35 mmol) and DMAP (1.7 mmol). Then, dibenzyl
phosphite (24.5 mmol) was added dropwise. When the reaction was complete as
indicated by TLC, KH2PO4 (aq., 0.5 M) was added and the mixture was allowed to warm
to room temperature. An ethyl acetate extract (3 × 50 mL) was washed with saturated
NaCl (100 mL) followed by water (100 mL) and dried over anhydrous Na2SO4. The
solvent was evaporated under reduced pressure and the product isolated by flash column
chromatography (hexane: ethyl acetate gradient, 88:12 to 50:50).

8.1.2.1. Dibenzyl (2-methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin2-yl)phenyl) phosphate (7b) was prepared according to the general procedure above
from

4-(3-hydroxy-4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-

one (7) in 74.3% yield as a yellow oil; IR (NaCl film) νmax: 1750 cm-1 (β-lactam -C=O);
1

H NMR (400 MHz, CDCl3) δ 3.73 (s, 6H, 2 × OCH3), 3.78 (s, 3H, OCH3), 3.84 (s, 3H,

OCH3), 4.25 (d, 1H, J=2 Hz, H3), 4.78 (d, 1H, J=2 Hz, H4), 5.15-5.18 (m, 4H, CH2), 6.60
(s, 2H, ArH), 6.98 (d, 1H, J=8 Hz, ArH), 7.20 (m, 2H, ArH), 7.33-7.41 (m, 15H, ArH);
C NMR (100 MHz, CDCl3) δ 55.6 (OCH3), 55.6 (OCH3), 60.5 (OCH3), 62.9 (C3), 64.5
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(C4), 69.5 (OCH2), 69.6 (OCH2), 94.3 (CH, Ar), 112.9 (CH, Ar), 119.3 (CH, Ar), 122.8
(CH, Ar), 127.0 (CH, Ar), 127.4 (CH, Ar), 127.5 (CH, Ar), 127.6 (CH, Ar), 128.2 (CH,
Ar), 128.2 (CH, Ar), 128.6 (CH, Ar), 133.1 (C, Ar), 134.0 (C, Ar), 153.1 (C, Ar), 165.0
(C=O); HRMS: calculated for C39H38NO9PNa: 718.2182; found 718.2172 [M+Na]+.
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8.1.3. General method for synthesis of phosphates 7a, 8a and 9a
β-Lactams 7b, 8b or 9b (2 mmol) were dissolved in ethanol: ethyl acetate (50 mL; 1:1
mixture) and hydrogenated over 10% Pd/C (1.2 g) until complete on TLC; typically less
than 3 hours. The catalyst was removed by filtration through Celite, the solvent was
evaporated under reduced pressure and the product was isolated by flash column
chromatography (hexane: ethyl acetate gradient, 88:12 to 50:50).

8.1.3.1.

2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-

yl)phenyl dihydrogen phosphate (7a) was prepared from 7b as described in the general
method above. The product was obtained as a brown oil in 93% yield; IR (KBr disk) νmax:
1747 cm-1 (β-lactam -C=O); 1H NMR (400 MHz, DMSO-d6) δ 3.59 (s, 3H, OCH3), 3.67
(s, 6H, 2 × OCH3), 3.77 (s, 3H, OCH3), 4.43 (d, 1H, J=2.5 Hz, H3), 5.24 (d, 1H, J=2.5 Hz,
H4), 6.63 (s, 2H, ArH), 7.09 (d, 1H, ArH, J=8.5 Hz), 7.35 (m, 1H, ArH), 7.36-7.42 (m,
5H, ArH), 7.51 (s, 1H, ArH);
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C NMR (100 MHz, DMSO-d6) δ 56.1 (OCH3), 56.2

(OCH3), 60.5 (OCH3), 62.2 (C3), 64.0 (C4), 95.5 (CH, Ar), 113.7 (CH, Ar), 119.6 (CH,
Ar), 122.9 (CH, Ar), 127.9 (CH, Ar), 128.0 (CH, Ar), 128.2 (CH, Ar), 128.7 (CH, Ar),
129.4 (CH, Ar), 129.7 (CH, Ar), 133.5 (C, Ar), 134.3 (C, Ar), 135.2 (C, Ar), 150.9 (C,
Ar), 151.0 (C, Ar), 153.6 (C, Ar), 165.8 (C=O); HRMS: Calculated for C25H26NNaO9PS:
538.1243; found 538.1252 [M+Na]+.

8.1.4. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl
2-(((benzyloxy)carbonyl)amino)propanoate

(7e).

N-Benzyloxycarbonyl-L-alanine
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(0.23 mmol), DCC (0.23 mmol) and DMAP (0.23 mmol) were stirred in anhydrous DCM
(5 mL) at 0 ºC. A solution of the β-lactam 7 (0.23 mmol) in anhydrous DCM (5 mL) was
added dropwise over five min. The reaction was stirred for 16 h under a nitrogen
atmosphere at ambient temperature. Reaction was monitored via TLC. After 24 hours,
dichloromethane (50 mL) was added and the mixture was filtered. The solvent was
removed by washing with water (5 × 50 mL). The organic solvent containing the product
was evaporated under reduced pressure. The product was isolated by flash column
chromatography (dichloromethane: methanol gradient), to afford the product 7e (88%).
IR (NaCl film) νmax: 1752.9 (β-lactam -C=O); 1H NMR (400 MHz, CDCl3) δ 1.62 (3H, d,
J=7 Hz, CH3), 3.75-3.92 (m, 12H, 4 × OCH3), 4.30-4.32 (m, 1H, H3), 4.69 (1H, q, J=7
Hz, CH), 4.83-4.87 (m, 0.5H, CH, H4), 5.15-5.44 (m, 0.5H, CH, H4), 5.39-5.44 (2H, m,
OCH2), 6.61-6.64 (2H, m, ArH), 6.88-6.95 (m, 1H, ArH), 7.01-7.03 (m, 1H, ArH), 7.167.17 (m, 1H, ArH), 7.29-7.41 (m, 10H, ArH).13C NMR (100 MHz, CDCl3) δ 18.7 (CH3),
18.8 (CH3), 49.7 (C), 56.1 (OCH3), 60.9 (OCH3), 63.4 (C3), 63.8 (C3), 64.9 (C4), 65.0
(CH2), 67.1 (CH2), 94.8 (CH, Ar), 94.9 (CH, Ar), 111.1 (CH, Ar), 112.0 (CH, Ar), 113.1
(CH, Ar), 113.1 (CH, Ar), 117.8 (CH, Ar), 120.8 (CH, Ar), 124.6 (CH, Ar), 124.6 (CH,
Ar), 127.5 (CH, Ar), 127.9 (CH, Ar), 128.0 (CH, Ar), 128.1 (CH, Ar), 128.2 (CH, Ar),
128.6 (CH, Ar), 129.0 (CH, Ar), 129.1 (CH, Ar), 129.9 (CH, Ar), 130.5 (CH, Ar), 133.6
(C, Ar), 133.7 (C, Ar), 134.5 (C, Ar), 134.5 (C, Ar), 134.8 (C, Ar), 136.2 (C, Ar), 139.9
(C, Ar), 146.4 (C, Ar), 146.9 (C, Ar), 151.2 (C, Ar), 153.5 (C, Ar), 153.6 (C, Ar), 155.6
(C, Ar), 165.5 (C=O), 165.6 (C=O), 171.0 (C=O), 171.1 (C=O); HRMS: Calculated for
C36H36N2O9Na: 663.2319; Found 663.2332 [M+Na]+.
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8.1.5. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl
2-(((benzyloxy)carbonyl)amino)-3-phenylpropanoate (7f). N-Benzyloxycarbonyl-Lphenylalanine (0.23 mmol), DCC (0.23 mmol) and DMAP (0.23 mmol) were stirred in
anhydrous DCM (5 mL) at 0 ºC. A solution of 7 (0.23 mmol) in anhydrous DCM (5 mL)
was added dropwise over five min. Following the method described above for the
preparation of 7e, the product 7f was isolated (79%). IR (NaCl film) νmax: 1754.7 (βlactam -C=O); 1H NMR (400 MHz, CDCl3) δ 3.24-3.38 (m, 2H, CH2), 3.75-3.86 (m,
12H, 4 × OCH3), 4.32 (m, 1H, H3), 4.87 (m, 1H, H4), 4.95-4.99 (m, 1H, CH), 5.13 (s, 2H,
CH2 ), 6.63 (s, 2H, ArH), 7.00-7.04 (m, 2H, ArH), 7.29-7.42 (m, 16H, ArH).
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C NMR

(100 MHz, CDCl3) δ 37.6 (CH2), 37.7 (CH2), 54.3 (C), 55.5 (OCH3), 55.6 (OCH3), 60.5
(OCH3), 62.9 (C3), 64.5 (C4), 66.6 (OCH2), 94.3 (CH, Ar), 112.6 (CH, Ar), 112.7 (CH,
Ar), 120.4 (CH, Ar), 124.2 (CH, Ar), 126.8 (CH, Ar), 127.0 (CH, Ar), 127.6 (CH, Ar),
127.8 (CH, Ar), 128.1 (CH, Ar), 128.2 (CH, Ar), 128.3 (CH, Ar), 128.7 (CH, Ar), 128.8
(CH, Ar), 129.0 (CH, Ar), 129.1 (CH, Ar), 129.4 (CH, Ar), 129.5 (CH, Ar), 133.1 (C,
Ar), 134.0 (C, Ar), 134.1 (C, Ar), 135.0 (C, Ar), 135.1 (C, Ar), 139.3 (C, Ar), 150.9 (C,
Ar), 153.1 (C, Ar), 155.2 (C, Ar), 164.9 (C=O), 165.0 (C=O), 169.1 (C=O), 169.2 (C=O);
HRMS: Calculated for C42H41N2O9: 717.2812; found 717.2813 [M+H]+.

8.1.6. Acetylamino-acetic acid 2-methoxy-5-[4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl]phenyl ester (7g). N-Acetylglycine (0.23 mmol), DCC (0.23
mmol) and DMAP (0.23 mmol) were stirred in anhydrous DCM (5 mL) at 0 ºC. A
solution of 7 (0.23 mmol) in anhydrous DCM (5 mL) was added dropwise over five min.
The reaction was stirred for 16 h under a nitrogen atmosphere at ambient temperature.
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Reaction was monitored via TLC. After 24 hours, dichloromethane (50 mL) was added
and the mixture was filtered. The solvent was removed by washing with water (5 × 50
mL). The organic solvent containing the product was evaporated under reduced pressure.
The product was isolated by flash column chromatography (dichloromethane: methanol
gradient), to afford the product (72%). IR (NaCl film) νmax: 1753.3 (β-lactam -C=O); 1H
NMR (400 MHz, CDCl3) δ 2.07 (s, 3H, CH3), 3.73 (s, 6H, 2 × OCH3), 3.79 (s, 3H,
OCH3), 3.84 (s, 3H, OCH3), 4.29 (d, 1H, J=2.5 Hz, H3), 4.32-4.33 (m, 2H, CH2), 4.86 (d,
1H, J=2 Hz, H4), 6.60 (s, 2H, ArH), 7.02 (d, 1H, J=8.5 Hz, ArH), 7.15 (m, 1H, ArH),
7.31-7.41 (m, 6H, ArH).
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C NMR (100 MHz, CDCl3) δ 22.5 (CH3), 40.7 (CH2), 55.6

(OCH3), 60.5 (OCH3), 62.9 (C3), 64.5 (C4), 94.3 (CH, Ar), 112.7 (CH, Ar), 120.2 (CH,
Ar), 124.3 (CH, Ar), 126.9 (CH, Ar), 127.6 (CH, Ar), 128.6 (CH, Ar), 129.5 (CH, Ar),
133.1 (C, Ar), 133.9 (C, Ar), 134.0 (C, Ar), 139.3 (C, Ar), 150.8 (C, Ar), 153.1 (C, Ar),
165.0 (C=O), 167.7 (C=O), 169.9 (C=O); HRMS: Calculated for C29H30NO8Na:
557.1900; found 557.1917 [M+Na]+.

8.1.7. 2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl
acetate (7i). The imine 12a (5mmol) and triethyl amine (15 mmol) were added to
anhydrous dichloromethane (50 mL) and the mixture heated to reflux under nitrogen
atmosphere. Acetyl chloride (7.5 mmol) was injected dropwise through a septum, and the
mixture was allowed to reflux for 3 h. The reaction mixture was then cooled, washed
with water, (2 × 50 mL) and sodium bicarbonate solution (aq., 50 mL). The organic layer
was dried with anhydrous Na2SO4, and the solvent evaporated to dryness in vacuo. The
residue was purified by flash chromatography (hexane ethyl acetate, 50:50) to afford the
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β-lactam product as colourless crystals from methanol (7%), Mp 70 oC. IR (KBr disk)
νmax: 1725.1 (β-lactam -C=O); 1H NMR (400 MHz, CDCl3) δ 2.12 (3H, s, CH3), 3.75
(6H, s, 2 × OCH3), 3.80 (3H, s, OCH3), 3.87 (3H, s, 2 × OCH3), 4.32 (1H, d, J=2.5 Hz,
H3), 4.86 (1H, d, J=2.5 Hz, H4), 6.64 (2H, s, ArH), 7.02 (1H, m, ArH), 7.13(1H, d, J=2
Hz, ArH), 7.27-7.40 (6H, m, ArH); HRMS: Calculated for C27H27NO7Na: 500.1685;
found: 500.1688 [M+Na]+.

8.1.8. 2-Methoxy-5--4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-yl)phenyl
benzoate (7j). The imine 12b (5mmol) and triethyl amine (15 mmol) were added to
anhydrous dichloromethane (50 mL) and the mixture heated to reflux under nitrogen
atmosphere. Phenylacetyl chloride (7.5 mmol) was injected dropwise through a septum,
and the mixture was allowed to reflux for 3 h, following the method described above for
the preparation of 7i. The β-lactam product 7j was obtained as colourless crystals from
methanol (8%), Mp 73 oC. IR (NaCl film) νmax: 1752.0 (β-lactam -C=O); 1H NMR (400
MHz, CDCl3) δ 3.84 (s, 6H, 2 × OCH3), 3.84 (s, 3H, OCH3), (s, 3H, OCH3), 4.36 (d, 1H,
J=2.9 Hz, H3), 4.90 (d, 1H, J=2.9 Hz, H4), 6.63 (s, 2H, ArH), 7.07-7.31 (m, 2H, ArH),
7.35-7.39 (m, 4H, ArH), 7.52-7.83 (m, 4H, ArH), 8.20-8.24, (m, 3H, ArH); HRMS:
Calculated for C32H29NO7Na: 562.1842; found: 562.1841 [M+Na]+.

8.1.9.

[3-(2-Bromoethoxy)-4-methoxybenzylidene]-(3,4,5-trimethoxyphenyl)amine

(12d). Imine 12c (5 mmol) and tertabutylammonium sulfate (4.5 mmol) were dissolved in
dibromoethane (50 mmol). Sodium hydroxide solution (1 M, 40 mL) was added to the
reaction mixture. The reaction was vigorously stirred for 16 h. Upon completion, the
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reaction mixture was diluted with dichloromethane (100 mL) and saturated sodium
hydrogen carbonate (100 mL). The organic phase was separated, while the aqueous phase
was extracted with dichloromethane (2 × 100 mL). The organic phases were combined,
dried over Mg2SO4 and evaporated to dryness in vacuo. The resulting crystals were
recrystallised from ethanol to afford the product (83%); IR (KBr disk) νmax: 1622.8
(C=N); 1H NMR (400 MHz, CDCl3) δ 3.89-3.97 (m, 12H, 3 × OCH3), 3.74 (t, 2H, J=6.5
Hz, CH2Br), 4.46 (t, 2H, CH2O), 6.51 (s, 2H, ArH), 6.99 (d, 1H, J=8.5 Hz, ArH), 7.39 (d,
1H, J=8 Hz, ArH), 7.62 (s, 1H, ArH), 8.40 (s, 1H, HC=N); 13C NMR (100 MHz, CDCl3)
δ 29.1 (CH2Br), 55.6 (OCH3), 60.6 (OCH3), 68.4 (CH2O), 97.6 (CH, Ar), 110.8 (CH, Ar),
111.2 (CH, Ar), 124.8 (CH, Ar), 128.8 (CH, Ar), 135.7 (C, Ar), 143.0 (C, Ar), 147.5 (C,
Ar), 153.1 (C, Ar), 158.4 (C=N); HRMS: Calculated for C19H23NO5Br: 424.0760; found
424.075 [M+H]+.

8.1.10.

4-[3-(2-Bromoethoxy)-4-methoxyphenyl]-3-phenyl-1-(3,4,5-

trimethoxyphenyl)azetidin-2-one (7k). Imine 12d (2.0 mmol) and triethylamine (2.6
mmol) were dissolved in anhydrous dichloromethane (10 mL). A solution of phenylacetyl
chloride (2.6 mmol) in anhydrous dichloromethane (5 mL) was added slowly via syringe.
The reaction was refluxed for two hours, then allowed cool and evaporated to dryness.
The residue was purified by flash chromatography (hexane: ethyl acetate, 1:1) to afford
7k as a resin (29%); IR (NaCl film) νmax 1749.8 (β-lactam C=O); 1H NMR (400 MHz,
CDCl3) δ 3.64 (t, 2H, CH2Br, J=6.5 Hz), 3.75 (s, 6H, OCH3), 3.80 (s, 3H, OCH3), 3.91 (s,
3H, OCH3), 4.29-4.34 (m, 3H, OCH2, H3), 4.86 (d, 1H, J=2.5 Hz), 6.63 (s, 2H), 6.93-6.96
(m, 2H), 7.05-7.08 (m, 1H), 7.34-7.40 (m, 5H, ArH); 13C NMR (100 MHz, CDCl3) δ 28.4
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(CH2Br), 55.6 (OCH3), 59.9 (OCH3), 60.5 (OCH3), 63.4 (C3), 64.5 (C4), 68.9 (OCH2),
94.4 (CH, Ar), 111.7 (CH, Ar), 112.1 (CH, Ar), 119.7 (CH, Ar), 126.9 (CH, Ar), 127.5
(CH, Ar), 128.6 (CH, Ar), 129.4 (CH, Ar), 130.5 (CH, Ar), 133.2 (C, Ar), 134.2 (C, Ar),
147.7 (C, Ar), 149.8 (C, Ar), 153.1 (C, Ar), 165.1 (C=O); HRMS: Calculated for
C27H28NO6NaBr: 564.0998, found 564.1005 [M+Na]+.

8.1.11.

4-[4-Methoxy-3-(2-methylaminoethoxy)phenyl]-3-phenyl-1-(3,4,5-

trimethoxyphenyl)azetidin-2-one (7l). β-Lactam 7k (0.2 mmol) and methylamine 2.0 M
solution (4.0 mmol) were dissolved in anhydrous tetrahydrofuran (10 mL) in a high
pressure tube. The sealed tube was heated to 60 ºC for 6 h. The reaction mixture was
allowed cool and sodium carbonate/sodium hydrogen carbonate pH 10 buffer solution
was added (25 mL). The reaction mixture was extracted with dichloromethane (3 × 50
mL). The combined organic phases were dried over Mg2SO4 and evaporated to dryness in
vacuo. The residue was purified using flash chromatography (hexane: ethyl acetate, 1:1)
to afford 7l as a resin (30%); IR (NaCl film) νmax 1746.6 (β-lactam C=O); 1H NMR (400
MHz, CDCl3) δ 2.70 (s, 3H, NCH3), 3.24 (m, 2H, CH2), 3.75 (s, 6H, OCH3), 3.79 (s, 3H,
OCH3), 3.88 (s, 3H, OCH3), 4.22-4.30 (m, 3H, CH, OCH2), 4,57 (broad s, 1H, NH), 4.86
(d, 1H, CH, J=2 Hz), 6.62 (s, 2H, ArH), 6.93-6.96 (m, 2H), 7.05-7.08 (m, 1H), 7.33-7.41
(m, 5H, ArH);
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C NMR (100 MHz, CDCl3) δ 34.0 (NCH3), 48.6 (CH2), 55.6 (OCH3),

55.9 (OCH3), 60.5 (OCH3), 63.3 (C3), 64.5 (C4), 66.0 (OCH2), 94.4 (CH, Ar), 102.9 (CH,
Ar), 111.5 (CH, Ar), 111.7 (CH, Ar), 119.7 (CH, Ar), 127.0 (CH, Ar), 127.5 (CH, Ar),
127.8 (CH, Ar), 127.9 (CH, Ar), 128.5 (CH, Ar), 128.6 (CH, Ar), 129.7 (CH, Ar), 130.5
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(CH, Ar), 133.2 (C, Ar), 134.1 (C, Ar), 147.7 (C, Ar), 149.5 (C, Ar), 153.1 (C, Ar), 165.2
(C=O); HRMS: Calculated for C28H33N2O6: 493.2334; found 493.2337 [M+H]+.

8.1.12. General method for synthesis of amides 10a-10f and 11a-11h
To a stirred solution of the appropriate amino β-lactam 10 or 11 (4.76 mmol) in
anhydrous DMF (30 mL) were added DCC (5.7 mmol), Cbz- or Fmoc-protected L-amino
acid (5.7 mmol) and HOBt.H2O (7.3 mmol) at room temperature. After 24 hours, ethyl
acetate (50 mL) was added and the mixture was filtered. DMF was removed by washing
with water (5 by 50 mL). The organic solvent containing the product was evaporated
under reduced pressure. The product was isolated by flash column chromatography
(dichlormethane: methanol gradient).

8.1.12.1.

Benzyl

(1-((4-(2-(4-methoxyphenyl)-4-oxo-1-(3,4,5-

trimethoxyphenyl)azetidin-3-yl)phenyl)amino)-1-oxo-3-phenylpropan-2yl)carbamate (10e) was prepared from 10 and Cbz-protected phenylalanine following
the general method above and was isolated as a yellow gel in 28% yield; IR (NaCl film)
νmax: 1743 cm-1 (β-lactam -C=O), 1689 cm-1 (-C=O); 1H NMR (400 MHz, CDCl3) δ 3.113.25 (m, 2H, CH2), 3.74 (s, 6H, 2 × OCH3), 3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.01
(m, 2H, CH2), 4.24 (d, 1H, CH), 4.55 (d, 1H, CH), 4.82 (d, 1H, J=2.5 Hz, H4), 5.49 (s,
1H), 6.61 (s, 2H, ArH), 6.96 (d, 2H, J=9.0 Hz, ArH), 7.25-7.35 (m, 18H, ArH), 7.67 (s,
1H, ArH);

13

C NMR (100 MHz, CDCl3) δ 38.4 (CH2), 53.0 (CH), 54.9 (OCH3), 55.6

(OCH3), 60.5 (OCH3), 63.5 (C3), 64.1 (C4), 66.6 (OCH2), 66.9 (OCH2), 94.4 (CH, Ar),
114.2 (CH, Ar), 120.2 (CH, Ar), 125.4 (CH, Ar), 126.8 (CH, Ar), 127.6 (CH, Ar), 127.7
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(CH, Ar), 127.9 (CH, Ar), 128.1 (CH, Ar), 128.5 (CH, Ar), 128.7 (CH, Ar), 128.8 (CH,
Ar), 133.2 (C, Ar), 134.0 (C, Ar), 135.4 (C, Ar), 135.7 (C, Ar), 153.0 (C, Ar), 159.5 (C,
Ar), 165.2 (C=O), 168.6 (C=O); HRMS: Calculated for C42H41N3O8Na: 738.2791; found
738.2777 [M+Na]+.

8.1.12.2.

(9H-Fluoren-9-yl)methyl

(1-((2-methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-

trimethoxyphenyl)azetidin-2-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
(11d) was prepared from 11 and Fmoc-protected valine following the general method
above and was isolated as a brown oil in 51% yield; IR (NaCl film) νmax: 1748 cm-1 (βlactam -C=O), 1686 cm-1 (C=O); 1H NMR (400 MHz, CDCl3) δ 1.01-1.04 (m, 6H, 2 ×
CH3), 2.20-2.28 (m, 1H, CH), 3.75-3.88 (m, 12H, 4 × OCH3), 4.18 (m, 2H), 4.24 (m, 1H,
CH), 4.43-4.48 (m, 2H), 4.92 (s, 1H, CH), 5.49 (d, 1H, J=8.6 Hz), 6.66 (s, 2H, ArH), 6.81
(s, 1H, ArH), 6.92-6.94 (m, 1H, ArH), 7.16-7.18 (m, 1H, ArH), 7.31-7.45 (m, 9H, ArH),
7.62-7.63 (m, 2H, ArH), 7.77 (m, 2H, ArH), 8.23 (s, 1H, ArH), 8.54 (m, 1H, ArH);
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NMR (100 MHz, CDCl3) δ 17.5 (CH3), 18.8 (CH3), 30.7 (CH), 46.7 (CH), 55.1 (OCH3),
55.5 (OCH3), 55.6 (OCH3), 55.7 (OCH3), 60.5 (OCH3), 61.0 (OCH3), 63.3 (C3), 63.6
(C3), 64.3 (C4), 64.4 (C4), 66.8 (CH2), 94.4 (CH, Ar), 94.4 (CH, Ar), 94.5 (CH, Ar), 110.1
(CH, Ar), 110.3 (CH, Ar), 111.3 (CH, Ar), 111.4 (CH, Ar), 115.8 (CH, Ar), 116.3 (CH,
Ar), 117.9 (CH, Ar), 119.6 (CH, Ar), 120.8 (CH, Ar), 120.9 (CH, Ar), 124.6 (CH, Ar),
126.2 (CH, Ar), 126.6 (CH, Ar), 126.8 (CH, Ar), 127.0 (CH, Ar), 127.1 (CH, Ar), 127.2
(CH, Ar), 127.3 (CH, Ar), 127.4 (CH, Ar), 128.5 (CH, Ar), 128.6 (CH, Ar), 129.4 (CH,
Ar), 133.2 (C, Ar), 133.4 (C, Ar), 133.9 (C, Ar), 134.1 (C, Ar), 134.4 (C, Ar), 136.1 (C,
Ar), 140.8 (C, Ar), 143.2 (C, Ar), 143.3 (C, Ar), 147.8 (C, Ar), 153.0 (C, Ar), 156.0 (C,
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Ar), 165.3 (C=O), 172.1 (C=O); HRMS: Calculated for C45H45N3O8Na: 778.3104; found
778.3107 [M+Na]+.

8.1.13. General methods for removal of Fmoc protecting group for preparation of
10g-10j and 11i-11o
General method 1: To the Fmoc-amino acid amide (2.1 mmol) at room temperature in
CHCl3 (55 mL) was added piperidine (2 mL). The mixture was stirred and monitored
until complete on TLC. The solvent was evaporated under reduced pressure. The product
was isolated by flash column chromatography (dichloromethane: methanol gradient,
100:0 to 90:10).

General method 2: To the Fmoc-amino acid amide dissolved in CH2Cl2 (minimum
volume, 1-2 mL) was added 1-octanethiol (10 equiv.) and TBAF (2 equiv.). The mixture
was stirred at room temperature until complete on TLC, typically within 10 minutes. The
solvent was evaporated under reduced pressure and product was isolated by flash column
chromatography (dichloromethane: methanol gradient, 100:0 to 90:10).

8.1.13.1.

2-Amino-N-(2-methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-

trimethoxyphenyl)azetidin-2-yl)phenyl)-3-methylbutanamide (11l) was prepared from
11d by general method 2 and was obtained as a yellow oil in 57% yield; IR (NaCl film)
νmax: 3380.25 cm-1 (NH2), 1747.97 cm-1 (β-lactam -C=O), 1676.35 cm-1 (-C=O); 1H NMR
(400 MHz, CDCl3) δ 0.88 (d, 3H, J=7 Hz), 1.05 (d, 3H, J=7 Hz), 2.35 (m, 1H), 3.75-3.77
(m, 10H), 3.92 (s, 3H), 4.29-4.37 (m, 1H), 4.78-4.92 (m, 1H), 6.65 (s, 2H), 6.79 (s, 1H),
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6.93 (m, 1H), 7.13 (m, 1H), 7.29-7.36 (m, 5H), 8.66 (d, 1H, J=13 Hz), 10.00 (d, 1H, J=13
Hz); 13C NMR (100 MHz, CDCl3) δ 19.2 (CH3), 19.3 (CH3), 30.4 (CH), 30.5 (CH), 55.1,
55.5 (OCH3), 55.6 (OCH3), 55.7 (OCH3), 60.4 (OCH3), 60.5 (OCH3), 63.4 (C3), 63.6
(C3), 64.2 (C4), 64.3 (C4), 94.4 (CH, Ar), 94.5 (CH, Ar), 110.0 (CH, Ar), 110.2 (CH, Ar),
110.3 (CH, Ar), 111.0 (CH, Ar), 115.8 (CH, Ar), 117.5 (CH, Ar), 117.9 (CH, Ar), 120.0
(CH, Ar), 120.1 (CH, Ar), 126.9 (CH, Ar), 127.0 (CH, Ar), 127.3 (CH, Ar), 127.4 (CH,
Ar), 127.5 (CH, Ar), 127.6 (CH, Ar), 128.3 (CH, Ar), 129.3 (CH, Ar), 129.4 (CH, Ar),
133.3 (C, Ar), 133.4 (C, Ar), 133.9 (C, Ar), 134.2 (C, Ar), 134.3 (C, Ar), 134.5 (C, Ar),
136.7 (C, Ar), 147.1 (C, Ar), 148.0 (C, Ar), 148.1 (C, Ar), 153.0 (C, Ar), 165.3 (C=O),
165.3 (C=O), 172.3 (C=O); HRMS: Calculated for C30H36N3O6: 534.2604; found
534.2584 [M+H]+.

8.1.14. Synthesis of 7h, 10k-10m and 11p-11r
The carboxybenzyl or benzyl protected compound 7e, 10e, 10f, 10j, 11h, 11n or 11o (2
mmol) was dissolved in ethanol: ethyl acetate (50 mL; 1:1 mixture) and hydrogenated
over 1.2g of 10% palladium on carbon until complete on TLC, typically less than 2 hours.
The catalyst was filtered, the solvent was evaporated under reduced pressure and the
product was isolated by flash column chromatography (dichloromethane: methanol
gradient, 100:0 to 90:10).
8.1.14.1.

2-Methoxy-5-(4-oxo-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-

yl)phenyl 2-aminopropanoate (7h) was prepared from compound 7e following the
procedure above in 58% yield. IR (NaCl film) νmax: 1748.1 (β-lactam -C=O); 1H NMR
(400 MHz, CDCl3) δ 1.54 - 1.56 (m, 3H, CH3), 3.76-3.92 (m, 12H, 4 × OCH3), 4.30-4.32

31

(m, 1H, H3), 4.83-4.88 (m, 1H, H4), 6.62 - 6.64 (m, 2H, ArH), 6.88 - 6.95 (m, 1H, ArH),
7.01-7.04 (m, 1H, ArH), 7.14-7.15 (m, 1H, ArH), 7.34-7.41 (m, 5H, ArH);
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C NMR

(100 MHz, CDCl3) δ 20.6 (CH3), 56.0 (OCH3), 56.1 (OCH3), 60.9 (OCH3), 63.5 (C3),
63.8 (C3), 64.9 (C4), 65.0 (C4), 94.8 (CH, Ar), 94.9 (CH, Ar), 111.1 (CH, Ar), 112.1 (CH,
Ar), 113.0 (CH, Ar), 117.9 (CH, Ar), 120.6 (CH, Ar), 124.5 (CH, Ar), 127.4 (CH, Ar),
127.9 (CH, Ar), 128.0 (CH, Ar), 129.0 (CH, Ar), 129.1 (CH, Ar), 129.9 (CH, Ar), 130.5
(CH, Ar), 133.7 (C, Ar), 134.4 (C, Ar), 134.5 (C, Ar), 134.8 (C, Ar), 140.3 (C, Ar), 146.4
(C, Ar), 146.9 (C, Ar), 153.5 (C, Ar), 153.6 (C, Ar), 165.6 (C=O); HRMS: Calculated for
C28H31N2O7: 507.2131; found 507.2152 [M+H]+.

8.1.14.2.

2-Amino-N-(4-(2-(4-methoxyphenyl)-4-oxo-1-(3,4,5-

trimethoxyphenyl)azetidin-3-yl)phenyl)-3-phenylpropanamide (10k) was prepared
from 10e following the procedure above as a yellow oil in 51% yield; IR (NaCl film)
νmax: 1742 cm-1 (β-lactam -C=O), 1684 cm-1 (-C=O); 1H NMR (400 MHz, CDCl3) δ 2.822.88 (m, 1H, CH2), 3.35-3.39 (m, 1H, CH2), 3.79-3.85 (m, 13H, 4 × OCH3, CH), 4.26 (s,
1H), 4.84 (d, 1H, J=2.5 Hz), 6.62 (s, 2H), 6.97 (d, 3H, J=8.5 Hz), 7.25-7.39 (m, 10H),
9.52 (s, 1H, NH); 13C NMR (100 MHz, CDCl3) δ 40.0 (CH2), 54.4 (OCH3), 55.6 (OCH3),
56.2 (CH), 58.8 (CH), 60.5 (OCH3), 63.5 (C3), 64.2 (C4), 94.4 (CH, Ar), 114.2 (CH, Ar),
119.7 (CH, Ar), 124.1 (CH, Ar), 126.6 (CH, Ar), 126.9 (CH, Ar), 127.6 (CH, Ar), 127.8
(CH, Ar), 128.1 (CH, Ar), 128.2 (CH, Ar), 128.3 (CH, Ar), 128.4 (CH, Ar), 128.7 (CH,
Ar), 128.9 (CH, Ar), 129.3 (CH, Ar), 129.9 (CH, Ar), 133.2 (C, Ar), 133.9 (C, Ar), 136.2
(C, Ar), 136.9 (C, Ar), 153.0 (C, Ar), 159.4 (C, Ar), 159.5 (C, Ar), 164.7 (C=O), 165.3
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(C=O), 171.7 (C=O), 174.0 (C=O); HRMS: Calculated for C34H36N3O6: 582.2604; found
582.2613 [M+H]+.

8.2. Solubility measurement. Solubility testing was carried out on selected samples 7,
7a, 8, 8a, 9, 9a, 10, 10g, 10i, 10k, 10l, 11, 11j, 11k, 11l, 11p and 11q as follows: An
amount of compound approximately equal to 5 mg was accurately weighed and
suspended in a corresponding amount of distilled water in a vial (Wheaton sample vials
with rubber lined caps) to give a concentration of 1 mg/mL. This suspension was placed
on a shaking plate (IKA® MTS 2/4 digital) and agitated at 300 shakes/minute for 24
hours. After 24 hours, the vials were removed from the shaking plate. The
solution/suspensions were filtered and the filtrate was assayed by HPLC using the
conditions described above for purity testing to determine the amount of compound in
solution.

8.3. Biochemical Methods
8.3.1. Antiproliferative studies. All assays were performed in triplicate for the
determination of mean values reported. Compounds were assayed as the free bases
isolated from reaction. The human breast tumour cell line MCF-7 was cultured in Eagles
minimum essential medium in a 95% O2/5% CO2 atmosphere with 10% fetal bovine
serum, 2 mM L-glutamine and 100 µg/mL penicillin/streptomycin. The medium was
supplemented with 1% non-essential amino acids. Cells were trypsinised and seeded at a
density of 2.5 × 104 cells/mL in a 96-well plate and incubated at 37 oC, 95%O2/5% CO2
atmosphere for 24 h. After this time they were treated with 2 µL volumes of test
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compound which had been pre-prepared as stock solutions in ethanol to furnish the
concentration range of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control
wells contained the equivalent volume of the vehicle ethanol (1% v/v). The culture
medium was then removed and the cells washed with 100 µL phosphate buffered saline
(PBS) and 50 µL MTT (1 mg/mL solution in PBS) added. Cells were incubated for 2 h in
darkness at 37 oC. At this point solubilization was begun through the addition of 200 µL
DMSO and the cells maintained at room temperature in darkness for 20 min to ensure
thorough colour diffusion before reading the absorbance. The absorbance value of control
cells (no added compound) was set to 100% cell viability and from this graphs of
absorbance versus cell density per well were prepared to assess cell viability and from
these, graphs of percentage cell viability versus concentration of compound added were
drawn.

8.3.2. Tubulin polymerisation assay. The effect of selected compounds on the
polymerisation of purified bovine brain tubulin was determined spectrophotometrically
by monitoring the change in turbidity. Lyophilised tubulin (Cytoskeleton, Denver, CO)
was re-suspended in ice cold G-PEM buffer (80 mM PIPES pH 6.9, 0.5 mM MgCl2,
1mM EGTA, 1 mM GTP, 10.2% (v/v) glycerol) and added to wells on a half volume 96
well plate containing the designated concentration of drug or vehicle. Samples were
mixed well and tubulin assembly was monitored at A340 nm at 30 sec intervals for 60 min
at 37oC in a Spectramax 340PC spectrophotometer (Molecular Devices). IC50 values were
calculated at 30 mins using GraphPad Prism software (GraphPad Software, Inc.).
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8.3.3. Immunofluorescence and confocal microscopy. For immunofluorescence, MCF7 cells were seeded at 1 × 105 per well on BD falcon four well chamber glass slides (BD
Biosciences, San Jose, USA. Cells were treated with vehicle [1% ethanol (v/v)]; 2, 8a,
9a, 10k, [100 nM] or 11l [1 µM] for 16 h. Following treatment, cells were washed gently
in PBS, fixed for 30 min in methanol at -20 oC. Following washes in PBST (PBS and
0.1% Triton-X-100), cells were blocked in 5% BSA diluted in PBST (blocking buffer).
Cells were then incubated with mouse anti-tubulin (DM1A (Merck Chemicals Ltd); 1:20
for 1 h at room temperature. Following washes in PBST cells were incubated with
fluorescein isothiocyanate (FITC) conjugated rabbit anti-mouse (Dakocytomation, UK);
1:100 for 1 h at room temperature. Following washes in PBST, the cells were mounted in
Ultra Cruz Mounting Media (Santa Cruz Biotechnology, Santa Cruz, CA) containing 4,6diamino-2-phenolindol dihydrochloride (DAPI). Confocal images were captured using
the OLYMPUS 1X81 microscope coupled with OLYMPUS FLUOVIEW Ver 1.5
software. All images in each experiment were collected on the same day using identical
parameters.

8.3.4. Determination of DNA content by flow cytometry. MCF-7 cells were seeded at
1 × 105 cells/cm3. After 24 h, cells were treated with vehicle [1% ethanol (v/v)]; 2, 7a, 8a,
9a, 10k, [100 nM] or 11l [1 µM] for 48 h. Cells were harvested by centrifugation at 800 ×
g for 10 min. Cell pellets were re-suspended in PBS and fixed in 70% ethanol: PBS
overnight at -20 oC. Following centrifugation cell pellets were re-suspended in PBS
supplemented with 0.5 mg/ml RNase and 0.15 mg/ml propidium iodide (PI). Following a
30 min incubation at 37oC in the dark the PI fluorescence was measured on a linear scale
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using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). The amount of
PI fluorescence is directly proportional to the amount of DNA present in each cell. The
relative content of DNA indicates the distribution of a population of cells throughout the
cell cycle. For example, cells in G0G1 are diploid and have a DNA content of 2N. Cells
with the G2M phases have a DNA content of 4N, while cells in S-phase have a DNA
content between 2N and 4N. Apoptotic cells are sub-diploid (<2N). Data collection was
gated to exclude cell debris and cell aggregates. At least 10,000 cells were analysed per
sample. All data were recorded and analysed using the CellQuest software (Becton
Dickinson).

8.4. Computational Procedures. For ligand preparation, all compounds were built in
Molecular Operating Environment 2011.10 (MOE 2011.10) [38] and energy minimised.
Conformers of these compounds were generated in MOE 2011.10 using the conformation
search option. The stochastic method was chosen with an iteration limit of 100. All other
parameters were remained unchanged. For the receptor preparation, the PDB entry 1SA0
was downloaded from the Protein Data Bank (PDB) [33]. All waters were retained in
both isoforms. Addition and optimisation of hydrogen positions for these waters was
carried out using MOE 2011.10 ensuring all other atom positions remained fixed. Using
the reported X-ray structure of tubulin co-crystallised with a colchicine derivative,
DAMA-colchicine (PDB entry-1SA0), possible binding orientations of the β-lactam
ligands were probed with the docking program MOE 2011.10. Docking was carried out
using MOE 2011.10, using the DAMA-colchicine to identity the binding site. Each

36

conformation was subsequently docked using the Triangle Matcher placement
methodology setting. All the default parameters remained unchanged.
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Table Captions
Table 1. Antiproliferative activities and physiochemical properties of β-lactam phosphate
esters
a

IC50 values are half maximal inhibitory concentrations required to inhibit the growth of

MCF-7. Values represent the mean ± S.E.M for at least three independent experiments
performed in triplicate. The IC50 value obtained for 2 in this assay was 5 nM for MCF-7
and is in good agreement with the reported values for 2 using the MTT assay on human
MCF-7 breast cancer cell line [31, 39, 40].
b

c

CLogP value calculated using ChemDraw Ultra and refers to CLogPoct/water

Solubility value taken as the maximum value from n=3, where each sample was assayed

three times
d

Solubility is below the level of detection of the assay

Table 2. Antiproliferative activity and solubility of β-lactam amino acid amides derived
from 10
a

IC50 values are half maximal inhibitory concentrations required to inhibit the growth of

MCF-7. Values represent the mean ± S.E.M for at least three independent experiments
performed in triplicate
b

c

CLogP value calculated using ChemDraw Ultra and refers to CLogPoct/water

Solubility value taken as the maximum value from n=3, where each sample was assayed

three times
d

Solubility is below the level of detection of the assay; nd=not determined
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Table 3. Antiproliferative activity and solubility of β-lactam amino acid amides derived
from 11
a

IC50 values are half maximal inhibitory concentrations required to inhibit the growth of

MCF-7. Values represent the mean ± S.E.M for at least three independent experiments
performed in triplicate.
b

c

CLogP value calculated using ChemDraw Ultra and refers to CLogPoct/water

Solubility value taken as the maximum value from n=3, where each sample was assayed

three times
d

e

f

Solubility is below the level of detection of the assay; nd= not determined

In murine 26 colon cells [21]

Human plasma, pH 7.2-7.5 [21]

Figure captions
Figure 1. Phosphate prodrugs of tubulin-binding agents NAC, CA-4, CA-1 and
phenstatin

Figure 2. Amino-acid prodrugs of amino analogues of CA-4 and CA-2

Figure 3. Antiproliferative β-lactams chosen for prodrug development. One
enantiomer is illustrated.

Figure 4. Effects of compounds 7, 7a, 9 and 9a on the inhibition of tubulin
polymerisation.

43

Effects of compounds 7, 7a, 9 and 9a (10 µM) on in vitro tubulin polymerisation.
Purified bovine tubulin and GTP were mixed in a 96-well plate. The reaction was started
by warming the solution from 4 oC to 37oC. Ethanol (1%v/v) was used as a vehicle
control. The effect on tubulin assembly was monitored in a Spectramax 340PC
spectrophotometer at 340nm at 30 second intervals for 60 minutes at 37 oC. The graph
shows one representative experiment. Each experiment was performed in triplicate.

Figure 5. Effects of compound 11l on the inhibition of tubulin polymerisation.
Dose-response effect of compound 11l on in vitro tubulin polymerisation. Purified bovine
tubulin and GTP were mixed in a 96-well plate. The reaction was started by warming the
solution from 4 oC to 37oC. Ethanol (1%v/v) was used as a vehicle control. The effect on
tubulin assembly was monitored in a Spectramax 340PC spectrophotometer at 340nm at
30 second intervals for 60 minutes at 37 oC. The graph shows one representative
experiment. Each experiment was performed in triplicate.

Figure 6. Compound 2 and β-lactams 8a and 9a depolymerise the microtubule
network of MCF-7 cells resulting in mitotic catastrophe. MCF-7 cells were treated
with vehicle control (1% ethanol (v/v), A+E), or compound 2 (B+F), 8a (C+G) or 9a
(D+H) (all 100 nM) for 16 h. Cells were fixed in methanol and stained with α-tubulin
mAbs (green) and counterstained with DAPI (blue). Images were captured by confocal
microscopy coupled with OLYMPUS FLUOVIEW software. Bar equal to 40 µm.
Representative confocal micrographs of three separate experiments are shown.
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Figure 7. Compound 2 and β-lactams 10k and 11l depolymerise the microtubule
network of MCF-7 cells resulting in mitotic catastrophe. MCF-7 cells were treated
with vehicle control (1% ethanol (v/v), A+D), compound 10k (B+E; 100 nM) or 11l
(C,+F; 1 µM) for 16 h. Cells were fixed in methanol and stained with α-tubulin mAbs
(green) and counterstained with DAPI (blue). Images were captured by confocal
microscopy coupled with OLYMPUS FLUOVIEW software. Bar equal to 20 µm.
Representative confocal micrographs of three separate experiments are shown.

Figure 8. Effects of 2 and β-lactams 7, 8, 9, 7a, 8a, 9a, 10k, 11l on the cell cycle.
Percentages of cells in (A) sub-G1 and (B) G2/M phase after treatment with βlactams. MCF-7 cells were untreated (U), treated with vehicle control (V, 1% ethanol
(v/v)), or compound 2, 7, 8, 9, 7a, 8a, 9a, 10k (100 nM) or 11l (1 µM) for 48 h. Values
represent the mean ± SEM for at least three independent experiments. Using one –way
anova followed by Bonferroni's Multiple Comparison Test, there is no statistical
difference between all β-lactam compounds for percentage of cells in sub-G1. G2/M
p<0.001 for all compounds compared to vehicle with no statistical difference between
parent compounds and derivatives.

Figure 9. 2D representation of the binding interactions of (A) 10 and (B) 10k with the
colchicine binding site of tubulin.

Figure 10. 2D representation of the binding interactions of (A) 11 and (B) 11l with the
colchicine binding site of tubulin.
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Scheme Captions
Scheme 1. Preparation of β-lactam phosphate esters 7a, 8a, 9aa
a

Reagents and conditions: (a) Dibenzyl phosphite, dimethyl phosphite, or diethyl

phosphite, DIPEA, DMAP, CCl4, CH3CN (b) Pd/C, H2, EtOH:EtOAc (1:1) (c) (i)
BrSi(CH3)3, CH2Cl2 (ii) Na2S2O3. (Bn = -CH2C6H5)
*Only one enantiomer is illustrated

Scheme 2. Synthesis of β-lactams 7e-7la
a

Reagents and conditions: (a) DCC, DMAP (b) H2, Pd, EtOh, EtOAc (c) Et3N,

C6H5CH2COCl,

CH2Cl2

(d)

BrCH2CH2Br,

(nBu)4NHSO4,

NaOH;

(e)

Et3N,

C6H5CH2COCl, CH2Cl2; (f) MeNH2

Scheme 3. Preparation of β-lactams 10a-10j and 11a-11oa
a

Reagents and conditions: (a) N-protected L-amino acid, anhydrous DMF, DCC (polymer

supported), HOBt.H2O, stirring, rt; (b) TBAF, 1-octanethiol, CH2Cl2, rt

Scheme 4. Preparation of β-lactams 10k-10m and 11p-11ra
a

Reagents and conditions: (a) H2, Pd/C, EtOAc: EtOH 1:1, rt
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Table 1.
IC50 MCF-7

CLogPb

(nM)a

Solubility
(mg/mL)c

R1=

R2=

7

H

C6H5

9.6 ± 2.6[4]

3.14

0d

7a

P(O)(OH)2

C6H5

71 ± 35

2.09

0.30

8

H

7.0 ± 2.0[5]

2.79

0d

8a

P(O)(OH)2

20 ± 8

1.74

0.45

9

H

p-C6H4OH

0.8 ± 0.4[4]

2.47

0d

9a

P(O)(OH)2

p-C6H4OH

22 ± 11

1.43

0.14
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Table 2.
Structure

Amino acid

IC50 (nM)a

CLogPb

Solubility
(mg/mL)c

R=
10g

H

Gly

91 ± 10

1.99

0.06

10h

CH3

Ala

35 ± 20

2.30

nd

10i

(CH2)4NH2

Lys

690 ± 700

2.00

0d

10k

CH2C6H5

Phe

27 ± 0.3

3.71

0.14

10l

CH(CH3)2

Val

50 ± 20

3.22

0.004

Ser

860 ± 300

1.13

nd

50 ± 20 [4]

2.65

0

10m CH2OH
10

Parent compound
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Table 3.
Structure

Amino acid

IC50 MCF-7

CLogPb

(nM)a

Solubility
(mg/mL)c

R=
11i

H

Gly

1100 ± 900

1.55

nd

11j

CH3

Ala

760 ± 230

1.86

0.37

11k

CH2C6H5

Phe

1130 ± 500

3.28

0d

11l

CH(CH3)2

Val

460 ± 200

2.79

0.11

11m

(CH2)4NH2

Lys

9800 ± 2000

1.56

nd

11p

CH(CH3)C2H5

Ile

1100 ± 900

3.32

0.11

11q

CH2OH

Ser

780 ± 200

0.70

0.20

11r

CH2C6H4OH

Tyr

740 ± 60

2.61

nd

11

Parent compound (Figure 3)

650 ± 10 [4]

3.00

0d

37 e

0.87

0.11f

5a
Ser
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